ProfileGDS5678 / 1450417_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 55% 58% 55% 56% 59% 59% 57% 56% 56% 57% 54% 60% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7404362
GSM967853U87-EV human glioblastoma xenograft - Control 23.369155
GSM967854U87-EV human glioblastoma xenograft - Control 33.4891858
GSM967855U87-EV human glioblastoma xenograft - Control 43.3338155
GSM967856U87-EV human glioblastoma xenograft - Control 53.3604456
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6188459
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6347559
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4310457
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3898356
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3951556
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4469957
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2936554
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6234660
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.448957